ALK and non-small cell lung carcinoma: Another Phase III study (64), ALINA, found that alectinib markedly improved DFS compared with platinum-based chemotherapy in surgically resected stage IB–IIIA NSCLC patients with ALK fusions (HR, 0.24, P < 0.001).